financetom
Business
financetom
/
Business
/
Roblox Insider Sold Shares Worth $3,248,845, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Roblox Insider Sold Shares Worth $3,248,845, According to a Recent SEC Filing
Jan 21, 2025 3:21 PM

05:51 PM EST, 01/21/2025 (MT Newswires) -- Mark Reinstra, Chief Legal Officer and Corporate Secretary, on January 16, 2025, sold 50,000 shares in Roblox ( RBLX ) for $3,248,845. Following the Form 4 filing with the SEC, Reinstra has control over a total of 504,315 shares of the company, with 281,161 shares held directly and 223,154 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1315098/000131509825000005/xslF345X05/wk-form4_1737499355.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
-- Air Canada Brief: Now Down Less Than 5%, Was Down 5.5% After Reporting Q2 Preliminary Results Largely Below Last Year; Full-Year Guidance Lowered
-- Air Canada Brief: Now Down Less Than 5%, Was Down 5.5% After Reporting Q2 Preliminary Results Largely Below Last Year; Full-Year Guidance Lowered
Jul 22, 2024
09:55 AM EDT, 07/22/2024 (MT Newswires) -- Price: 16.21, Change: -0.86, Percent Change: -5.04 ...
PAR Technology Completes TASK Group Acquisition
PAR Technology Completes TASK Group Acquisition
Jul 22, 2024
09:55 AM EDT, 07/22/2024 (MT Newswires) -- PAR Technology ( PAR ) said Monday it has completed its acquisition of TASK Group, an Australian foodservice transaction platform. The company said the acquisition price consisted of approximately $131.5 million in cash and nearly 2.2 million shares of PAR Technology's ( PAR ) common stock. Shares of PAR Technology ( PAR )...
aTyr Pharma Completes Enrollment in Phase 3 Trial of Efzofitimod to Treat Pulmonary Sarcoidosis
aTyr Pharma Completes Enrollment in Phase 3 Trial of Efzofitimod to Treat Pulmonary Sarcoidosis
Jul 22, 2024
09:51 AM EDT, 07/22/2024 (MT Newswires) -- aTyr Pharma, Inc. ( ATYR ) said Monday it has completed enrollment in its phase 3 trial of efzofitimod to potentially treat people with pulmonary sarcoidosis. The trial enrolled 268 people at 85 centers in nine countries and exceeded its target enrollment, the company said, adding that topline results are expected in Q3...
Strata Skin Sciences Secures Approval for XTRAC Momentum 1.0 Device in Japan
Strata Skin Sciences Secures Approval for XTRAC Momentum 1.0 Device in Japan
Jul 22, 2024
09:54 AM EDT, 07/22/2024 (MT Newswires) -- Strata Skin Sciences ( SSKN ) said Monday that Japan's Ministry of Health, Labor, and Welfare has approved its excimer laser device, XTRAC Momentum 1.0. The device will be immediately launched in Japan through the medical technology company's partner and distributor JMEC, the company said. Strata Skin Sciences ( SSKN ) said that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved